Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19
Luis H. Paz Rios,
Iva Minga,
Esther Kwak,
Ayman Najib,
Ashley Aller,
Elizabeth Lees,
Victor Macrinici,
Kaveh Rezaei Bookani,
Amit Pursnani,
Joseph Caprini,
Alex C. Spyropoulos,
Alfonso Tafur
Affiliations
Luis H. Paz Rios
Cardiovascular Division, Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Iva Minga
Cardiovascular Division, Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Esther Kwak
Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Ayman Najib
Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Ashley Aller
Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Elizabeth Lees
Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Victor Macrinici
Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Kaveh Rezaei Bookani
Cardiovascular Division, Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Amit Pursnani
Cardiovascular Division, Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Joseph Caprini
Pritzker School of Medicine, University of Chicago, Chicago, Illinois, United States
Alex C. Spyropoulos
Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, NY, NY, United States
Alfonso Tafur
Cardiovascular Division, Department of Medicine, NorthShore University Health System, Evanston, Illinois, United States
Introduction Severe novel corona virus disease 2019 (COVID-19) causes dysregulation of the coagulation system with arterial and venous thromboembolism (VTE). We hypothesize that validated VTE risk scores would have prognostic ability in this population. Methods Retrospective observational cohort with severe COVID-19 performed in NorthShore University Health System. Patients were >18 years of age and met criteria for inpatient or intensive care unit (ICU) care. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) and Caprini scores were calculated and patients were stratified. Results This study includes 184 patients, mostly men (63.6%), Caucasian (54.3%), 63 years old (interquartile range [IQR]: 24–101), and 57.1% of them required ICU care. Twenty-seven (14.7%) thrombotic events occurred: 12 (6.5%) cases of disseminated intravascular coagulation (DIC), 9 (4.9%) of pulmonary embolism, 5 (2.7%) of deep vein thrombosis, and 1 (0.5%) stroke. Among them, 86 patients (46.7%) died, 95 (51.6%) were discharged, and 3 (1.6%) were still hospitalized. “Moderate risk for VTE” and “High risk for VTE” by IMPROVE score had significant mortality association: (hazard ratio [HR]: 5.68; 95% confidence interval [CI]: 2.93–11.03; p < 0.001) and (HR = 6.22; 95% CI: 3.04–12.71; p < 0.001), respectively, with 87% sensitivity and 63% specificity (area under the curve [AUC] = 0.752, p < 0.001). “High Risk for VTE” by Caprini score had significant mortality association (HR = 17.6; 95% CI: 5.56–55.96; p < 0.001) with 96% sensitivity and 55% specificity (AUC = 0.843, p < 0.001). Both scores were associated with thrombotic events when classified as “High risk for VTE” by IMPROVE (HR = 6.50; 95% CI: 2.72–15.53; p < 0.001) and Caprini scores (HR = 11.507; 95% CI: 2.697–49.104; p = 0.001). Conclusion The IMPROVE and Caprini risk scores were independent predictors of mortality and thrombotic events in severe COVID-19. With larger validation, this can be useful prognostic information.